DG

Devichand Gulabchand Jain

Active Director Designated Partner DIN 11218465
DIN 11218465 First appointment Jul 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Devichand Gulabchand Jain

Data last updated:

Devichand Gulabchand Jain is a Designated Partner at New Chintamani Pharma Llp (since 2025).

DIN 11218465
Primary Designation Designated Partner
First Appointment 28 Jul 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner28 Jul 20252025Active

Board colleagues of Devichand Gulabchand Jain

NameDINCompanyDesignation
Bharat Rajmal Oswal11218464New Chintamani Pharma LlpDesignated Partner
Rushikesh Anil Pisal11218466New Chintamani Pharma LlpDesignated Partner

Directorship timeline

Open interactive timeline →
New Chintamani Pharma Llp
Premium access

Shareholding and investment profile for Devichand Gulabchand Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Devichand Gulabchand Jain

Devichand Gulabchand Jain currently holds 1 directorship: New Chintamani Pharma Llp (Designated Partner, since 28 Jul 2025).

Devichand Gulabchand Jain was first appointed on 28 Jul 2025 as Designated Partner at New Chintamani Pharma Llp.

The current boards of Devichand Gulabchand Jain's companies include Bharat Rajmal Oswal (New Chintamani Pharma Llp), Rushikesh Anil Pisal (New Chintamani Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available